Nervonik Inc. is a stealth-mode startup company that has developed a novel and miniaturized neuromodulation device for therapeutic applications.
Location: United States, California, Palo Alto
Total raised: $65.5M
Investors 6
| Date | Name | Website |
| 10.07.2026 | US Venture... | usvp.com |
| 18.08.2021 | Life Scien... | lifescienc... |
| - | Camford Ca... | camford.co... |
| 29.04.2025 | Foothill V... | foothill.v... |
| 10.08.2022 | Xandex Ven... | xandexvent... |
| - | DHVC | dh.vc |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 27.04.2026 | Series B | $52.5M | - |
| 12.03.2025 | Series A | $13M | - |
Mentions in press and media 11
| Date | Title | Description |
| 27.04.2026 | Nervonik Raises $52.5M in Series B Funding | Nervonik, a Los Angeles, CA-based clinical-stage medical device company, raised $52.5M in Series B funding. The round was led by Amzak Health, with participation from Elevage Medical Technologies, U.S. Venture Partners (USVP), Lumira Ventur... |
| 27.04.2026 | Nervonik: $52.5 Million Series B Raised To Advance Peripheral Nerve Stimulation Therapy | Nervonik, a clinical-stage medical device company focused on next-generation peripheral nerve stimulation, announced it has secured $52.5 million in an oversubscribed Series B financing round. The round was led by Amzak Health, with partici... |
| 27.04.2026 | Nervonik Announces $52.5M Series B Financing | LOS ANGELES, CA, Nervonik, Inc., a clinical-stage medical device company, announced the closing of a $52.5 million Series B financing led by Amzak Health. >> Click here for more funding data on Nervonik >> To export Nervonik fu... |
| 27.04.2026 | Nervonik Raises $52.5M for Nerve Stim Tech | Nervonik Inc., the Los Angeles-based clinical-stage bioelectronic medicine innovator, has announced the successful oversubscribed financing of a $52.5 million Series B led by Sofinnova Partners. This round represents a major step forward in... |
| 13.03.2025 | Nervonik: A New Dawn in Chronic Pain Management | Chronic pain is a silent epidemic. It creeps into lives, turning vibrant days into shadows. Over 50 million Americans suffer from it. Traditional treatments often fall short, leaving patients trapped in a cycle of opioids and side effects. ... |
| 12.03.2025 | Nervonik: $13 Million (Series A) Raised For Improving Peripheral Nerve Stimulation For Chronic Pain Relief | Nervonik – a medical device company developing an opioid-free peripheral nerve stimulation (PNS) system – announced it has closed a $13 million Series A funding round. This funding round was led by U.S. Venture Partners (USVP), with partici... |
| 04.03.2025 | Nervonik Raises $13 Million in Series A Financing to Advance Next-Generation Peripheral Nerve Stimulation for Chronic Pain Relief | - |
| 04.03.2025 | Nervonik Raises $13M in Series A Financing | Nervonik, a Los Angeles, CA-based provider of a medical device company developing an opioid-free peripheral nerve stimulation (PNS) system, raised $13M in Series A funding. The round was led by U.S. Venture Partners (USVP), with participati... |
| 04.03.2025 | Nervonik Receives $13M Series A | LOS ANGELES, CA, Nervonik, a medical device company developing an opioid-free peripheral nerve stimulation (PNS) system, has successfully closed a $13 million Series A funding round. >> Click here for more funding data on Nervonik &g... |
| - | Nervonik | “Nervonik – Miniaturized neuromodulation devices for therapeutic applications” |
Show more